

PMB and EVEON have signed a development and supply agreement for radiopharmaceutical equipments

Grenoble (France), March 30th 2017 – EVEON, designer and manufacturer of smart medical devices for the preparation and administration of drugs, is announcing the signing of a framework contract for the development and supply of radiochemistry automatons. These automatons will be incorporated into PMB's LOTUS equipments (ALCEN Group), with the special purpose of being able to locally produce radiolabelled molecules for PET imaging¹. The first automatons will be delivered in 2018.

Molecular imaging, as a tool for diagnosis and treatment, is on its way to revolutionizing healthcare, particularly in oncology, but also in cardiac, neurological, and endocrine diseases. PET is mainly used to detect cancer cells. This technique has a high success rate for detecting and locating tumours. It is also used to follow the evolution of pathologies before or after treatment. It truly can improve survival odds by leading to adapted treatment and, in turn, greater efficacy.

The current PET imaging market is estimated to be worth 1.4 billion USD and continues to grow annually at a rate of 5 to 20% depending on the region. The number of procedures (8.6 million performed in 2016, in Europe and the USA combined²) is progressing strongly and should reach 11 million in 2021³.

PMB, a cyclotron specialist, develops integrated equipments for local production of radionuclides and synthesis of innovative, single-dose radiopharmaceuticals. With LOTUS, PMB plans to broaden its portfolio of biomarkers for diagnosis and make them more easily accessible. It will become possible to locally produce these compounds, alongside imaging centres. This is a paradigm shift for PET imaging, facilitating its use and allowing its deployment to rapidly accelerate. The innovative automated units designed and produced by EVEON respond to these specific challenges.



EVEON has been chosen to industrialize and manufacture the automatons, as a partner specialised in safe and automatic medical devices. EVEON provides its expertise in techniques, fluidics, and regulatory affairs, both during the industrialization and production phases. The company has already begun to develop a clinical and industrial version of the automatons, with the goal of delivering the first units to PMB as early as 2018. A LOTUS equipment will be assembled with one automaton for each radiopharmaceutical molecule produced. EVEON will be the supplier of the automatons.

¹ Positron Emission Tomography (PET) is a medical imaging technique that allows 3D measurements to be made of biological and metabolic functions, potentially even while in movement. It is most often combined with a conventional CT-scan (PET-CT scan). It enables the detection of tumours, physiological dysfunctions, neurological disorders, and metabolic disorders. It's one of the only techniques that makes it possible to visualize, characterize, and measure a biological process at a cellular or molecular level.

² Source : Carl von Gall MD, Siemens Healthineers Manager for Global Clinical Marketing dans le CR du Symposium AIPES oct 2016

³ Source : PET Market 2014 - Biotech Sys - Report 370

“The automaton is a key element of the LOTUS system. PMB has chosen to entrust the development and industrialisation of this subunit to EVEON because we are confident in their ability to successfully complete this project. We have been won over by their technology and their professionalism” said Ludovic Le Meunier, Deputy CEO of PMB.

“This new agreement demonstrates EVEON’s abilities for providing an innovative, integrated solution throughout an entire process from development to industrialisation. This agreement strengthens our position within the market of devices for professionals and marks our 3rd project in the field of oncology, and in this particular case, in radiochemistry” said Vincent Tempelaere, CEO of EVEON.

About PMB

For the past 40 years, PMB has designed, produced, and industrialized radiofrequency systems and subsystems as well as complex ceramic and metallic mechanical components. These components are resistant to harsh environments. They are destined to be used in the global industries of medical equipment, scientific research, defence & security, aerospace, and the nuclear sector. Armed with years of experience, PMB has broadened its activity to include design, development, and manufacturing of particle accelerators, electron guns, cyclotrons, and radiochemistry systems.

PMB is a company with a human touch that combines flexibility and responsiveness. Thanks to its practice of ground floor management, the company has built strong teams and brought together many talented individuals. Its constant efforts to promote professional training result in continual improvement of its abilities and expertise. PMB also pays special attention, each day, to the quality of each person’s work as part of a permanent concern for safety and clean, well-performing production tools.

Press contact: Ludovic Le Meunier, Ph. D. | +33 689 662 741 | llemeunier@pmb-alcen.com

More information at: www.pmb-alcen.com

About EVEON

Created in 2009, EVEON specializes in smart medical devices for safe and automatic preparation and administration of drugs. The medical devices developed ensure that the administered treatment is controlled, precise and constant, and are a guarantee of comfort and efficacy for patients and health professionals, at home or in medical and hospital environments. Thanks to its unique technology platform Intuity®, EVEON offers several families of medical device solutions according to the intended use. Protected by 13 patent families, EVEON medical devices are tailor-made for its customers and users.

As an ISO 13485 and ISO 9001 accredited company, EVEON has received many awards, including:

- 1st prize at the RTS/France 3 sponsored international competition Invent tomorrow in December 2014,
- 2nd prize from the Alliance pour le Génie Biologique et Médical (the Alliance for Medical and Biological Engineering) in July 2015,
- Two years in a row, the Pharmapack Europe Award Best Innovation Exhibitor, with special mentions *Convenience and Ease of use* in February 2016. (Intuity® Mix) and *Ease of use and Patient Compliance* in February 2017 (Intuity® Ject).

Press contact: Charlotte Reverand | +33 476 414 833 | cre@eveon.eu

More information at: www.eveon.eu

Press contact: Charlotte Reverand | +33 476 414 833 | cre@eveon.eu